Article
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2026
Harter P, Trillsch F, Okamoto A, Reuss A, Kim J-W, Rubio-Pérez M J, Vardar M A, Scambia G, Trédan O, Nyvang G-B, Colombo N, Bidziński M, Grimm C, Lheureux S, Van Nieuwenhuysen E, Heitz F, Wenham R M, Nishio S, Lim M C, Marquina G, Altundağ Ö, Bergamini A, Sabatier R, Wimberger P, Gold M A, Sehouli J, Park-Simon T-W, Kent E, Correa A, Aghajanian C
Abstract excerpt
BACKGROUND: Despite treatment advances in newly diagnosed advanced-stage ovarian cancer (aOC), improved outcomes are needed. PATIENTS AND METHODS: DUO-O (NCT03737643), a phase III placebo-controlled trial, enrolled patients with newly diagnosed aOC. Following one cycle of carboplatin/paclitaxel ± bevacizumab, patients without a tumor BRCA mutation (non-tBRCAm) were randomly assigned (1 : 1 : 1) at cycle 2 to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.